The final, formatted version of the article will be published soon. The use of glucagon-like peptide-1 (GLP-1) receptor agonists by young populations is rapidly increasing worldwide, thereby exposing ...

Here's what San Antonio doctors say about the widespread use of GLP-1 medications for obesity, diabetes and other conditions.

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

Delaware Attorney General Kathy Jennings is suing several drug manufacturers and pharmacy benefit managers for reported ...

Adults with type 1 diabetes who used a GLP-1 receptor agonist or other incretin-based drug had lower risk for all-cause ...

New studies raise the possibility that GLP-1 medications beat aspirin in reducing colorectal cancer risk, and may improve outcomes for people who do develop the disease.

Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its ...

Anyone who's been prescribed a GLP-1 drug like Ozempic, Wegovy or Trulicity to treat type 2 diabetes or help them lose weight ...

Metformin is the first choice medicine for type 2 diabetes. Meglitinides can cause low blood sugar, weight gain, and headaches. Biguanides can cause stomach pain and might lead to vitamin B12 ...